Cargando…
Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen
PURPOSE: Carrier screening identifies couples at high risk for conceiving offspring affected with serious heritable conditions. Minimal guidelines recommend offering testing for cystic fibrosis and spinal muscular atrophy, but expanded carrier screening (ECS) assesses hundreds of conditions simultan...
Autores principales: | Beauchamp, Kyle A., Johansen Taber, Katherine A., Muzzey, Dale |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752320/ https://www.ncbi.nlm.nih.gov/pubmed/30760891 http://dx.doi.org/10.1038/s41436-019-0455-8 |
Ejemplares similares
-
Clinical utility of expanded carrier screening: results-guided actionability and outcomes
por: Johansen Taber, Katherine A., et al.
Publicado: (2018) -
Clinical validity of expanded carrier screening: Evaluating the gene‐disease relationship in more than 200 conditions
por: Balzotti, Marie, et al.
Publicado: (2020) -
Evaluation and classification of severity for 176 genes on an expanded carrier screening panel
por: Arjunan, Aishwarya, et al.
Publicado: (2020) -
Sequencing as a first-line methodology for cystic fibrosis
carrier screening
por: Beauchamp, Kyle A., et al.
Publicado: (2019) -
Correction: Sequencing as a first-line methodology for cystic fibrosis carrier screening
por: Beauchamp, Kyle A., et al.
Publicado: (2019)